Back to search

Switzerland· 68199002

Qinlock 50 mg, Tabletten

A ripretinib product containing ripretinibum, registered in Switzerland by Deciphera Pharmaceuticals (Schweiz) AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EX19

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedQinlock 50 mg, TablettenATCL01EX19REGISTER NO.68199002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Ripretinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01EX19 (ripretinib), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Ripretinib · ATC L01EX19

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ripretinib costs, country by country.

Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.72 in France to $744.16 in Switzerland — a ×1040 gap.

  • Switzerland: $744.16 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Ripretinib · price per daily dose (0.15 g)

USD · FX 28 Sept 2026

  • CH Switzerland$744.16
  • FR France$0.72
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
ripretinibum
Manufacturer
Deciphera Pharmaceuticals (Schweiz) AG
Country
Switzerland (CH)
ATC code
L01EX19
ATC class
Ripretinib
Defined daily dose
0.15 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680681990024
    Fl 90 Stk
    CHF 18514.6

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

133 interactions on record for ripretinib.

Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ripretinib · interactions on record

133 records

  • 12 severe
  • 121 moderate

Most severe, free to view

  • KetoconazoleH02CA03severe
  • ClarithromycinJ01FA09severe
  • KetoconazoleJ02AB02severe
  • Darunavir and cobicistatJ05AR14severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c50a05ae-aa26-441f-9ee6-66ad806d36bb
GET /v1/drugs/c50a05ae-aa26-441f-9ee6-66ad806d36bb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "ripretinibum 50 mg",
  "valid_from": "2024-12-01",
  "limitations": "[{\"description\":\"QINLOCK ist in einer Dosierung von maximal 150 mg einmal täglich zur Behandlung von erwachsenen Patienten mit fortgeschrittenen gastrointestinalen Stromatumoren (GIST), die mindestens 3 vorherige Therapien mit Kinaseinhibitoren, darunter Imatinib, Sunitinib und Regorafenib, erhalten haben, angezeigt. Die Patienten müssen eine adäquate Organfunktion und Knochenmarksreserve aufweisen.<br>\\nDie Verordnung von QINLOCK darf ausschliesslich durch einen Facharzt für Onkologie mit Erfahrung in der Behandlung von GIST erfolgen. QINLOCK darf nicht mit anderen onkologischen Therapien kombiniert werden. Die Behandlung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nDie Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung QINLOCK einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21521.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21521.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-12-01\",\"validTo\":\"2026-11-30\"}]",
  "galenic_form": "Tabl 50 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2024-12-01",
  "self_retention_pct": 10
}

See everything about ripretinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.